Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daratumumab and ibrutinib work in treating patients with
chronic lymphocytic leukemia that has come back (relapsed) or has not responded to previous
treatment (refractory). Daratumumab is a monoclonal antibody which works with the body's
immune system to destroy cancer cells. Ibrutinib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Giving daratumumab and ibrutinib may
work better in treating patients with chronic lymphocytic leukemia compared to ibrutinib
alone.